drugset / Trial / NCT06199336
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety, immunogenicity and efficacy of JHM03 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The purpose of this study was to observe efficacy and safety of JHM03 compared with placebo and BOTOX® in moderate to severe glabellar lines.
Timeline
- Start
- 2024-01-19
- Primary completion
- 2024-09-09
- Completion
- 2024-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 0.5 ml | Intramuscular |
| Subject | JHM03 | Protein / enzyme biologic | 0.5 ml | Intramuscular |
Indications
No indication recorded.